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24.9 years (SD 14.4). Comparing the use of symptomatic medication (rescue and 
daily), diagnostic-tests, unscheduled medical care (allergist and emergency vis-
its) and sick-leave days number associated with SCIT treatment versus no SCIT 
treatment. SCIT treatment vs no SCIT treatment costs ratio was performed: Used 
resources (Symptomatic medication, unscheduled medical care, diagnostic-tests, 
and 3 years SCIT treatment and sick-leave days) were quantified in € . Efficacy 
(decreased resource usage) of first year treatment was assumed during the remain-
ing two years and during a three years follow-up period. Results: After a single 
year of SCIT all quantified resources (emergency and allergist visits, diagnostic tests, 
rescue medication and work absence days) diminished significantly (p< 0.05) from 
baseline. Reductions in resources’ cost: Hospital resources (100% in Hospitalizations; 
82% in additional visits to the allergist; 79% in ER visits). In medication: (56% in 
rescue medication; 63% in daily medication). In diagnostic tests: (75% in spirometry 
testing broncho-dilation; 72% in O2 saturation measuring; 90% in FeNO measuring 
and 81% in chest radiographs. In leave sick days 94%. Ratio of comparative calcu-
lation described as SCIT treatment versus non SCIT treatment (or conventional 
symptomatic treatment) is 0.8. ConClusions: Considering 3 years of SCIT, and 3 
follow up years of sustained efficacy after completing treatment, cost per patient 
SCIT treated is estimated at 20% below to the cost non SCIT treated patient. Direct 
costs are reduced by 64% and indirect costs by 94%. SCIT of hypoallergenic prepara-
tion of dust-mite allows cost savings vs conventional treatment.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
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ESTAbLIShIng ThE RELATIOnShIP Of InhALER SATISfAcTIOn, ADhEREncE, 
SmOkIng hISTORY AnD ALLERgIc RhInITIS WITh PATIEnT OuTcOmES: REAL 
WORLD ObSERvATIOnS In uS ADuLT ASThmA PATIEnTS
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objeCtives: Improving asthma control has more recently focused on potentially 
modifiable clinical and behavioural characteristics including correct inhaler tech-
nique, treatment of concomitant allergic rhinitis (AR), adherence and smoking. 
This research aimed to establish the relationship of these factors with measures 
of asthma control and overall health status to add to the growing body of evi-
dence helping to optimize asthma management interventions. Methods: Data 
were drawn from the USA 2013 Respiratory Disease Specific Programme, a cross-
sectional survey of adult asthma patients consulting for routine care. Partial Least 
Squares Path Modelling was used to quantify the inner model relationships between 
latent variables of patient-reported satisfaction of drug delivery, device functionality, 
device feedback (based on groupings of 12 inhaler device attributes), concomitant 
AR, adherence (Morisky Medication Adherence Scale), smoking history (smok-
ing status, years smoked, number smoked per day), patient reported outcomes 
(Asthma Control Test, Jenkins Sleep Questionnaire, EuroQol-5D-3L) and physician-
reported number of asthma exacerbations in the last 12 months. Patients not receiv-
ing inhaled maintenance therapy were excluded. Results: 243 patients met the 
inclusion criteria. All manifest variable loadings were positive, and a minimum 
Cronbach’s Alpha of 0.713 for the latent variables indicated unidimensionality of 
the manifest variables for each of the latent variables. Cross-loadings were also 
supportive of the hypothesised outer model. Better patient outcomes were sig-
nificantly associated with patient satisfaction with drug delivery (p= 0.002), adher-
ence (p= 0.049), negative smoking history (p< 0.001) and absence of concomitant 
AR (p= 0.005). The R2 value for outcomes was 13.3%, and the pseudo goodness of 
fit, which measures the overall prediction performance of the path model, was 
19.5%. ConClusions: Improving patient satisfaction with inhaler drug delivery 
represents one potentially modifiable aspect of asthma management alongside 
appropriate treatment of AR, smoking cessation and improving adherence, which 
are likely to have a positive impact on asthma patient outcomes.
PRS67
TEcEPOc II STuDY. hOW TO ImPROvE ThE InhALATIOn TEchnIquES In 
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objeCtives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with Chronic Obstructive Pulmonary Disease and 
the influence of patient´ preference. Methods: Design: Multicenter patients´ pref-
erence trial or comprehensive cohort design ISRCTN15106246. Patients: 465 COPD 
patients (to detect a difference between groups of 25%, 80% statistical power, 95% 
confidence level, 40% expected losses), with inhaled treatment, written consent. 
Non-probabilistic consecutive sampling. Allocation: Patients without strong pref-
erences for a treatment were randomised: RCT group (block randomization), and 
those with strong preferences were given their choice: PPS group. Variables: Primary 
outcomes: Performance of correct inhalation technique. Secondary outcomes: Pick flow, 
Baseline dyspnea index (BDI), Functional status (forced spirometry). Interventions: 
Intervention-A: Written information. A leaflet with the correct inhalation technique 
for the main inhaler devices used in our area. Intervention-B: Intervention-A + indi-
vidual training (by instructors). Follow-up: 12 month, visits: baseline, 1 month, 3rd 
month, 6th month, 12th month. Statiscal analysis: Mean, frequency, 95% confidence 
interval at baseline. Number Needed to Treat for a benefit (NNT) was calculated. 
Intention to treat analysis. Results: Predominance of males (91.4%), mean age 
69.8 years (CI95%, 69.00-70.59); FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed res-
piratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticoster-
compared with Symbicort® Turbuhaler®was based on a conservative assump-
tion. Results: An estimated 167,666 adult patients used Symbicort® Turbuhaler® 
annually in Sweden and were therefore eligible for treatment with DuoResp® 
Spiromax®, with 72,935 of these exhibiting poor inhalation technique. Based on 
the predicted improvement in inhalation technique with DuoResp® Spiromax® 
compared with Symbicort® Turbuhaler® – and assuming a hypothetical uptake of 
DuoResp® Spiromax®reaching 25% in years 4 and 5 – estimated societal cost savings, 
through the avoidance of 147,158 lost productive days, totalled SEK285.4 million 
(€ 31.2 million). ConClusions: DuoResp® Spiromax® has the potential to improve 
inhalation technique compared with Symbicort® Turbuhaler®, which would likely 
result in substantial societal cost savings.
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ImPAcT Of OmALIzumAb On ALL-cAuSE AnD ASThmA-RELATED hEALTh 
cARE RESOuRcE uTILISATIOn In PATIEnTS WITh mODERATE OR SEvERE 
PERSISTEnT ASThmA
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objeCtives: Increased health care resource utilisation (HCRU) is associated with 
inadequately controlled asthma. Here, we evaluate the impact of omalizumab 
on HCRU in patients with moderate or severe persistent asthma. Methods: A 
retrospective case-crossover study was conducted using the Truven MarketScan 
database. Data between 1-January-2007 to 30-September-2012 was collected for 
analysis. Patients included in the analysis had to have a diagnosis of moderate or 
severe persistent asthma, be ≥ 12 years of age during the analysis period, have had 
2 years of continuous enrolment (1 year pre/post omalizumab index date), and have 
had exposure to omalizumab continuously for ≥ 12 months. All-cause and asthma-
related HCRU during the years, pre and post omalizumab initiation, were compared 
using McNemar tests and 2-sided paired Student’s t test. Data were stratified by 
asthma severity based on NHLBI criteria. Results: A total of 429 patients (mean 
age, 46.6 years; female, 59.0%; Moderate= 340 [79.3%], Severe= 89 [20.7%]) from the 
database were included in the analysis. The use of omalizumab was associated with 
49.3% (p= 0.0003), 54.0% (p= 0.001), and 35.3% (p= 0.1466) reductions in the mean 
number of asthma-related ER visits and 69.2% (p= 0.0005), 65.5% (p= 0.0045), and 
80.0% (p= 0.0449) reduction in the mean number of asthma-related hospitalisations 
among All, Moderate, and Severe asthma patients, respectively. The mean length of 
stay for asthma-related hospitalisations was also reduced to 71.2% (p= 0.0002), 64.5% 
(p= 0.0016), and 90.6% (p= 0.0442) in All, Moderate, and Severe patients respectively. 
All-cause ER visits were reduced by 30.8% (p= 0.0014), 32.5% (p= 0.0045), and 25.0% 
(p= 0.1348), and hospitalisation reduced by 48.9%, 45.2%, and 64.7% (all p≤ 0.0155) in 
All, Moderate, and Severe asthma patients respectively. Cohort analysis of severe 
asthmatics was limited by sample size. ConClusions: In patients with moderate 
persistent asthma, omalizumab use was associated with significant reductions in 
all-cause and asthma-related HCRU.
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DEvIcE hAnDLIng ERRORS AnD ThE ImPAcT On quALITY Of LIfE AnD 
hEALTh cARE RESOuRcE uSE In ASThmATIc PATIEnTS
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objeCtives: Correct device technique has a significant influence on the delivery 
of inhaled therapies and can thus impact the control and management of asthma. 
The objective of this literature review was to examine the impact of device handling 
errors on QOL and health care resources to understand the potential value of a 
novel inhaler device for health care systems and patients. Methods: A literature 
search of articles published 2009–2013 was undertaken using MeSH terms and key 
words in MEDLINE®, supplemented by a grey literature review and searching of 
reference lists. Article selection and relevant data extraction were based on key 
words relating to handling error, QOL, and health care resource use. Results: Of 
575 potentially relevant publications, 22 were selected for in-depth review. Papers 
reported 25–73% of patients make critical handling errors that lead to no-dose or 
reduced-dose delivery on first use of devices. Incorrect inhaler use was four times 
more frequently reported in patients with uncontrolled asthma than in patients 
with controlled asthma. Poor asthma control also impacts resource use: poorly-
controlled patients made twice as many ER visits, and spent 2–3 times more time 
consulting with physicians than controlled patients (either physician visits or 
time speaking to physicians). Asthma control also impacts QOL: poorly-controlled 
patients reported health-state utility (EQ-5D) values of 0.52–0.69, compared to 0.88–
0.93 for well-controlled patients. ConClusions: Handling errors with devices can 
lead to poorly-controlled patients, resulting in reduced QOL and increased health 
care resource use. New inhaler devices represent an opportunity to reduce errors 
and improve asthma control, therefore improving QOL and reducing resource use. 
Further research is required to model the relationship between a reduction in han-
dling error and improved asthma control status, and the subsequent impact on 
resource use and QOL.
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mEDIum TERm AvOIDED cOSTS: hIgh-DOSE hYPOALLERgEnIc hOuSE 
DuST mITE PREPARATIOn ImmunOThERAPY vERSuS cOnvEnTIOnAL 
SYmPTOmATIc TREATmEnT
Hidalgo A.1, Rodríguez-Marco A.2, Arias-Muñoz M.2
1University of Castilla La Mancha, Toledo, Spain, 2MERCK S.L, Madrid, Spain
objeCtives: Quantifying cost difference between conventional symptomatic treat-
ment of mite allergy and subcutaneous specific immunotherapy (SCIT) with high 
doses of hypoallergenic dust-mite preparation. Methods: Observational, retro-
spective and multicenter study carried out in Spain in 2013.419 patients diagnosed 
with rhinitis and / or bronchial asthma for mite allergy were retrieved. Mean age 
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objeCtives: We aimed to assess the symptom burden and health related quality of 
life in patients with idiopathic lung fibrosis. Methods: Patients have been consec-
utively enrolled in an ongoing prospective non-interventional registry in Germany, 
investigating clinical characteristics, clinical management practices and quality of 
life. IPF diagnoses were in agreement with the international IPF guideline published 
in 2011. Clinical parameters and treatment practice were recorded by the physi-
cian. Patients filled out the EQ-5D-5L, St George’s Respiratory Questionnaire (SGRQ), 
WHO-5 and the UCSD shortness of breath (SOB) scale. The time trade off (TTO) score 
was calculated for the EQ-5D. Results: To date (04 June 2014), 421 patients with IPF 
have been enrolled in the registry (mean age 68.6±9.5; 77% male). The mean six-min-
ute walk distance was 271±200, mean % of predicted forced vital capacity was 72±20 
and the mean % predicted DLCO was 35±16. Patients were treated with oral steroids 
(22.1%, as monotherapy in 7.1%); N-acetylcysteine (34.8%), pirfenidone (47.2%), and 
long-term O2 therapy (34.4%). The physician rated the disease in 35.6% as stable, 
in 31.1% as slowly progressing and in 11.9% as rapidly progressing. One in four 
patients described their current state of health as at least good, and every fifth as 
poor. The mean EQ-5D TTO score was 0.8±0.2. 45% of the patients showed depressive 
symptoms based on the WHO-5. The mean SGRQ sum score was 47.7±20.1 describing 
difficulties with breathing in the previous 3 months. Higher EQ-5D TTO scores were 
significantly associated with a lower number of comorbid diseases (r= -0.31), higher 
6-minute walk distance (r= 0.20), higher FVC % pred (r= 0.27), less depression (r= 0.66) 
and lower SGRQ scores (r= -0.72). ConClusions: The IPF patients in this large reg-
istry had a more severe disease, a higher symptom burden and more compromised 
quality of life compared to recent randomised controlled trials.
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objeCtives: The Nighttime Symptoms of COPD Instrument (NiSCI) and Early 
Morning Symptoms of COPD Instrument (EMSCI) were developed to support treat-
ment benefit endpoints in global clinical trials. Translations that were conceptually 
equivalent to the English source version and easily understood by the target country 
populations were required. The purpose of this study was to translate and assess 
conceptual equivalence of the NiSCI and EMSCI for use in 14 countries: Austria, 
Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, The 
Netherlands, Poland, South Africa, Spain, and United Kingdom. Methods: The 
NiSCI and EMSCI were translated following ISPOR guidelines for linguistic valida-
tion of PRO measures (Wild et al., 2005) using the universal approach discussed in 
the second Task Force Report (Wild et al., 2009). The universal English, Spanish and 
French versions were previously translated (Eremenco et al., 2012). For the remain-
ing languages, two forward translations by native translators, reconciliation of the 
forwards, one back-translation by an English-speaker fluent in the target language, 
and final reconciliation by a native speaking language coordinator were conducted 
for both measures. Harmonization was performed to ensure conceptual equiva-
lence across languages. Interviews were conducted with five native-speaking COPD 
patients for each language/country combination. Interview data were analyzed to 
assess linguistic and cultural validity in each language and confirm conceptual 
equivalence. Results: Mean age of the sample (N= 80) was 60 years (range 41-83) 
and 54% were male. The translations were well understood and considered relevant, 
with patients raising only minor issues during interviews. Changes were made to the 
universal French (chest congestion), Hungarian (wheezing, chest congestion), Italian 
(chest congestion, moderately), and Lithuanian (instructions, wheezing, shortness 
of breath, experienced) following the patient interviews. ConClusions: All trans-
lated versions of the NiSCI and EMSCI in this study were found to be conceptually 
equivalent and acceptable for use in the 14 countries evaluated.
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TESTIng E-PRO DEvIcE uSAbILITY DuRIng ThE TRAnSLATIOn PROcESS:  
A cASE STuDY Of ThE ExAcT In 7 cOunTRIES
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objeCtives: Usability testing of electronic Patient-Reported Outcomes (ePRO) 
instruments is typically conducted during instrument development, in the lan-
guage/country of origin. It has been suggested that usability testing also be per-
formed during the translation process. It is unclear whether this additional step 
is necessary. In this study, usability testing was conducted as part of the linguis-
tic validation process in Simplified Chinese (China), German (Germany), French 
(France), Russian (Russia), and Spanish (Universal, tested in Chile, Spain, and US) 
for the Exacerbations of Chronic obstructive pulmonary disease Tool (EXACT), an 
e-PRO developed and tested in English (US). Methods: The translation process 
followed ISPOR guidelines (Wild et al., 2005). Cognitive interviews were conducted 
with 2-3 native-speaking COPD respondents per language/country combination 
in 2008. Subjects completed the EXACT in paper-pen screenshot format and were 
interviewed for translation validation. Subsequently they were instructed to use a 
PDA (Tungsten E2; CRF, Inc.) to complete the first 5 EXACT items and were inter-
viewed regarding device usability. Interviewers rated subjects’ ability to use the 
device. Results: Subjects (N= 20) were 45-84 years, 60% male, and 60% with second-
ary education or less. Most (n= 18) had not used a PDA previously; all (n= 20) reported 
oids (76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); 
oral-corticosteroids (1.3%). BDI: grade 2. Primary outcome: RCT cohorts: there was 
no difference between control and intervention A and there were statistically 
significative differences between intervention B versus control (p< 0.0001), NNT= 3.22 
(IC95%, 2.27-5.88) and versus intervention A, NNT= 4.16 (IC95%, 2.63-10). In the PPS 
cohorts: there was a difference (p< 0.0001) between intervention B versus interven-
tion A, NNT= 3.22 (IC95%, 2.32-5.55). The preferences enhanced a 6.7% the correct 
inhalation technique. ConClusions: The performance of a correct inhalation 
Technique improves with monitor training. The patients´ preferences enhance the 
efficacy of intervention.
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objeCtives: To test the efficacy of two educational interventions to improve the 
inhalation techniques per device in patients with COPD and the influence of patient´ 
preference. Methods: Design: Multicenter patients´ preference trial or compre-
hensive cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a 
difference between groups of 25%, 80% statistical power, 95% confidence level, 40% 
expected losses), with inhaled treatment, written consent. Non-probabilistic con-
secutive sampling. Allocation: Patients without strong preferences for a treatment 
are randomised: RCT group (block randomization), and those with strong prefer-
ences are given their choice: PPS group. Variables: Primary outcomes: Performance of 
correct inhalation technique. Independent variables: sex, age, Baseline dyspnea index 
(BDI), Functional status (forced spirometry). Interventions: Interv-A: Written infor-
mation. A leaflet with correct inhalation technique. Interv-B: Interv-A + individual 
training (by instructors). Follow-up: 3 month, visits: baseline (V0), 1 month (V1), 
3 month (V2). Statiscal analysis: Mean, frequency, 95% confidence interval. Intention 
to treat analysis. Results: Males (91.4%), mean age 69.8 years (CI95%, 69.00-70.59); 
FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed respiratory pattern (65.9%). Severity 
stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. BDI: grade 2. Devices use: 67.3% 
Handihaler (Hd), 54.8% Turbuhaler (Th), 31.8% Accuhaler (Acc), 26.9% pMDI. Correct 
Inhalation technique: hd: RCT-control: 11.7% V0,10% (V2); RCT-intervA: 10.9%, 17.5%; 
RCT-IntervB: 7.4%, 62.3% p< 0.0001. Th: RCT-control: 22% V0, 16.7% (V2); RCT-intervA: 
8.7%, 24.4%; RCT-IntervB: 7.5 %, 57.5% p< 0.0001. Acc: RCT-control: 16.1% V0, 25% (V2); 
RCT-intervA: 17.9%, 23.1%; RCT-IntervB: 11.5%, 74.1% p< 0.0001. pmDI: RCT-control: 
6.9% V0, 3.6% (V2); RCT-intervA: 12.5%, 19%; RCT-IntervB: 8.3%, 34.6% p= 0.025. 
There were statistically differences for all devices only in the intervention B arms 
(p< 0.0001). The preferences enhanced 1% for Handihaler, 12.7% for Accuhaler, 4.6% 
for Turbuhaler, 15.4% for pMDI the correct inhalation technique. ConClusions: 
The performance of a correct inhalation technique improves with monitor training 
for all devices. The patients´ preferences enhance the efficacy.
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objeCtives: To identify characteristics of dry powder inhalers (DPIs) considered 
important by asthma and chronic obstructive pulmonary disease (COPD) patients, 
in order to select attributes and attribute-levels for a discrete choice experi-
ment. Methods: Qualitative data was collected from a literature review performed 
to determine which inhaler attributes impact inhaler satisfaction and adherence 
among asthma and COPD patients using DPIs. Focus groups with asthma and COPD 
patients were conducted in France, with patients asked to cite and rate important 
features of their inhaler. Qualitative analysis of the transcripts was performed 
following International Society For Pharmacoeconomics and Outcomes Research 
(ISPOR) guidelines. Results: Results of the literature review revealed no overall 
consensus on the importance of different inhaler attributes in relation to inhaler 
satisfaction and adherence across studies. The most frequently reported attributes 
were: overall ease-of-use, low inspiratory flow requirements, presence of a dosing 
feedback mechanism, ergonomics of the inhaler mouthpiece, ease with which the 
device can be kept hygienic and the ease with which the medicinal dose can be pre-
pared. Four discussion groups were held, with thirty patients participating. Overall, 
the degree to which the inhaler can optimise treatment convenience appeared 
to be the most important attribute to patients. In agreement with results of the 
literature review, patients also rated the following inhaler attributes as being impor-
tant: size of the dose counter, ability to keep the mouthpiece hygienic, ergonomics 
of the inhaler mouthpiece, presence of a dosing feedback mechanism, ease with 
which a dose can be prepared, low inspiratory flow requirements. ConClusions: 
Results of this study provide an insight inhaler attributes most valued by asthma 
and COPD patients. Patients described their ideal inhaler to be small, with an ergo-
nomic mouthpiece and an easy to use dose preparation mechanism, and providing 
enough medicine for at least a month of treatment.
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